News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
337,336 Results
Type
Article (20147)
Company Profile (142)
Press Release (317047)
Section
Business (107629)
Career Advice (886)
Deals (19017)
Drug Delivery (99)
Drug Development (51600)
Employer Resources (79)
FDA (8027)
Job Trends (7872)
News (189960)
Policy (17769)
Tag
Academia (743)
Alliances (28621)
Alzheimer's disease (576)
Approvals (7980)
Artificial intelligence (81)
Bankruptcy (173)
Best Places to Work (5612)
Biosimilars (69)
Biotechnology (63)
Cancer (517)
Cardiovascular disease (59)
Career advice (717)
Cell therapy (77)
Clinical research (42377)
Collaboration (194)
Compensation (64)
COVID-19 (1090)
C-suite (57)
Data (549)
Diabetes (107)
Diagnostics (1869)
Drug pricing (96)
Earnings (38831)
Employer resources (73)
Events (48437)
Executive appointments (178)
FDA (8272)
Funding (149)
Gene therapy (88)
GLP-1 (572)
Government (1852)
Healthcare (6154)
Infectious disease (1137)
Inflammatory bowel disease (66)
Interviews (116)
IPO (7439)
Job creations (2471)
Job search strategy (659)
Layoffs (256)
Legal (4192)
Lung cancer (95)
Manufacturing (121)
Medical device (2347)
Medtech (2350)
Mergers & acquisitions (11601)
Metabolic disorders (359)
Neuroscience (731)
NextGen Class of 2024 (2426)
Non-profit (924)
Northern California (625)
Obesity (232)
Opinion (176)
Patents (67)
People (33435)
Pharmaceutical (75)
Phase I (13151)
Phase II (17984)
Phase III (14436)
Pipeline (211)
Podcasts (61)
Policy (70)
Postmarket research (1658)
Preclinical (4652)
Radiopharmaceuticals (159)
Rare diseases (132)
Real estate (3259)
Regulatory (12435)
Research institute (848)
Resumes & cover letters (143)
Southern California (572)
Startups (2075)
United States (5785)
Vaccines (212)
Weight loss (204)
Date
Today (68)
Last 7 days (474)
Last 30 days (1683)
Last 365 days (18334)
2024 (16242)
2023 (20205)
2022 (26956)
2021 (27700)
2020 (25748)
2019 (20700)
2018 (16054)
2017 (17908)
2016 (16755)
2015 (19437)
2014 (15278)
2013 (12975)
2012 (13953)
2011 (14261)
2010 (13106)
Location
Africa (416)
Asia (24909)
Australia (3379)
California (1396)
Canada (706)
China (140)
Colorado (59)
Connecticut (55)
Europe (53996)
Florida (186)
Illinois (139)
Indiana (111)
Kansas (56)
Maryland (230)
Massachusetts (1196)
Minnesota (86)
New Jersey (547)
New York (405)
North Carolina (347)
Northern California (625)
Ohio (61)
Pennsylvania (346)
South America (615)
Southern California (572)
Texas (176)
Washington State (138)
337,336 Results for "novo nordisk pharma gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon technology platform in an effort to find novel GLP-1 candidates with reduced dosing frequency.
November 4, 2024
·
1 min read
·
Annalee Armstrong
GLP-1
Novo Nordisk’s Ozempic Could Help Curb Cigarette Use in Diabetics: Study
Adding to growing evidence of its benefits beyond glucose control and weight loss, Novo Nordisk’s Ozempic could also potentially help diabetics quit smoking, according to new research.
July 30, 2024
·
2 min read
·
Tristan Manalac
Supply chain
Novo’s Ozempic to Remain in Shortage Into Q4 as Supply Woes Continue
Novo Nordisk’s continuing supply problems for semaglutide come as the pharma tries to expand the drug’s indication, opening it up to more patients—and potentially to heavier production pressures.
September 3, 2024
·
2 min read
·
Tristan Manalac
GLP-1
FDA Says All Doses of Novo’s Ozempic, Wegovy Now Available
Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up with demand for the blockbuster GLP-1 drugs.
October 31, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Novo’s Wegovy Comparable to Madrigal’s Rezdiffra in Phase III MASH Trial: Analysts
In part 1 of the pivotal ESSENCE trial, Novo Nordisk’s weight loss drug Wegovy demonstrated “statistically significant and superior improvement” in liver fibrosis in patients with metabolic dysfunction–associated steatohepatitis.
November 1, 2024
·
3 min read
·
Heather McKenzie
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
November 5, 2024
·
6 min read
Podcast
Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More
In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated steatohepatitis victory for Novo Nordisk’s Wegovy, growing excitement about CAR Ts for autoimmune disease and the ongoing controversy over HeLa cells.
November 6, 2024
·
1 min read
·
Heather McKenzie
Earnings
Novo Misses Overall Q3 Revenue Despite Beating Wegovy Sales Forecast, Narrows 2024 Outlook
Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year guidance for revenue and operating profit.
November 6, 2024
·
3 min read
·
Tristan Manalac
1 of 33,734
Next
